Deep-sequence phylogenetics to quantify patterns of HIV transmission in the context of a universal testing and treatment trial - BCPP/ Ya Tsie trial

  1. Lerato E Magosi  Is a corresponding author
  2. Yinfeng Zhang
  3. Tanya Golubchik
  4. Victor DeGruttola
  5. Eric Tchetgen Tchetgen
  6. Vladimir Novitsky
  7. Janet Moore
  8. Pam Bachanas
  9. Tebogo Segolodi
  10. Refeletswe Lebelonyane
  11. Molly Pretorius Holme
  12. Sikhulile Moyo
  13. Joseph Makhema
  14. Shahin Lockman
  15. Christophe Fraser
  16. Myron (Max) Essex
  17. Marc Lipsitch  Is a corresponding author
  18. on behalf of the Botswana Combination Prevention Project and the PANGEA consortium
  1. Harvard University, United States
  2. University of Pittsburgh Medical Center, United States
  3. University of Oxford, United Kingdom
  4. Harvard T H Chan School of Public Health, United States
  5. University of Pennsylvania, United States
  6. Centers for Disease Control and Prevention, United States
  7. Centers for Disease Control and Prevention, Botswana
  8. Ministry of Health, Botswana
  9. Botswana Harvard AIDS Institute Partnership, Botswana
  10. Brigham and Women's Hospital, United States
  11. Harvard TH Chan School of Public Health, United States

Abstract

Background: Mathematical models predict that community-wide access to HIV testing-and-treatment can rapidly and substantially reduce new HIV infections. Yet several large universal test-and-treat HIV prevention trials in high-prevalence epidemics demonstrated variable reduction in population-level incidence.

Methods: To elucidate patterns of HIV spread in universal test-and-treat trials we quantified the contribution of geographic-location, gender, age and randomized-HIV-intervention to HIV transmissions in the 30-community Ya Tsie trial in Botswana. We sequenced HIV viral whole genomes from 5,114 trial participants among the 30 trial communities.

Results: Deep-sequence phylogenetic analysis revealed that most inferred HIV transmissions within the trial occurred within the same or between neighboring communities, and between similarly-aged partners. Transmissions into intervention communities from control communities were more common than the reverse post-baseline (30% [12.2 - 56.7] versus 3% [0.1 - 27.3]) than at baseline (7% [1.5 - 25.3] versus 5% [0.9 - 22.9]) compatible with a benefit from treatment-as-prevention.

Conclusion: Our findings suggest that population mobility patterns are fundamental to HIV transmission dynamics and to the impact of HIV control strategies.

Funding: This study was supported by the National Institute of General Medical Sciences (U54GM088558); the Fogarty International Center (FIC) of the U.S. National Institutes of Health (D43 TW009610); and the President’s Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention (CDC) (Cooperative agreements U01 GH000447 and U2G GH001911).

Data availability

All relevant data are within the paper, figures and tables. HIV-1 viral whole genome consensus sequences are provided as a Dryad dataset (https://doi.org/10.5061/dryad.0zpc86706). HIV-1 reads are available on reasonable request through a concept sheet proposal to the PANGEA consortium. Contact details are provided on the consortium website (www.pangea-hiv.org).Code availability: Algorithms to estimate HIV transmission flows within and between population groups accounting for sampling variability and corresponding confidence intervals have been implemented as an R package, bumblebee that will be made available at the following URL: https://magosil86.github.io/bumblebee . A step-by-step tutorial on how to estimate HIV transmission flows with bumblebee and accompanying example datasets can be accessed at: https://github.com/magosil86/bumblebee/blob/master/vignettes/bumblebee-estimate-transmission-flows-and-ci-tutotial.md .

The following data sets were generated

Article and author information

Author details

  1. Lerato E Magosi

    Department of Epidemiology, Harvard University, Boston, United States
    For correspondence
    lmagosi@hsph.harvard.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3388-9892
  2. Yinfeng Zhang

    Division of Molecular and Genomic Pathology, University of Pittsburgh Medical Center, Pittsburgh, United States
    Competing interests
    No competing interests declared.
  3. Tanya Golubchik

    Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2765-9828
  4. Victor DeGruttola

    Department of Biostatistics, Harvard T H Chan School of Public Health, Boston, United States
    Competing interests
    No competing interests declared.
  5. Eric Tchetgen Tchetgen

    Department of Statistics, University of Pennsylvania, Philadelphia, United States
    Competing interests
    No competing interests declared.
  6. Vladimir Novitsky

    Department of Immunology and Infectious Disease, Harvard T H Chan School of Public Health, Boston, United States
    Competing interests
    No competing interests declared.
  7. Janet Moore

    Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, United States
    Competing interests
    No competing interests declared.
  8. Pam Bachanas

    Division of Global HIV/AIDS and TB, Centers for Disease Control and Prevention, Atlanta, United States
    Competing interests
    No competing interests declared.
  9. Tebogo Segolodi

    HIV Prevention Research Unit, Centers for Disease Control and Prevention, Gaborone, Botswana
    Competing interests
    No competing interests declared.
  10. Refeletswe Lebelonyane

    Ministry of Health, Gaborone, Botswana
    Competing interests
    No competing interests declared.
  11. Molly Pretorius Holme

    epartment of Immunology and Infectious Disease, Harvard T H Chan School of Public Health, Boston, United States
    Competing interests
    No competing interests declared.
  12. Sikhulile Moyo

    Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
    Competing interests
    No competing interests declared.
  13. Joseph Makhema

    Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana
    Competing interests
    No competing interests declared.
  14. Shahin Lockman

    Division of Infectious Diseases, Brigham and Women's Hospital, Boston, United States
    Competing interests
    Shahin Lockman, participates in a data safety monitoring board for NIH-funded study of PK of TB drugs and antiretrovirals in children and on a scientific advisory board for observational study of DTG programmatic rollout in Botswana. Is also a member of the Finance Board and a member of the Board of Directors for the Botswana Harvard AIDS Institute Partnership. Receives no financial compensation for these roles, and has no other competing interests to declare..
  15. Christophe Fraser

    Big Data Institute, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
    Competing interests
    No competing interests declared.
  16. Myron (Max) Essex

    Department of Immunology and Infectious Disease, Harvard T H Chan School of Public Health, Boston, United States
    Competing interests
    No competing interests declared.
  17. Marc Lipsitch

    Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, United States
    For correspondence
    mlipsitc@hsph.harvard.edu
    Competing interests
    Marc Lipsitch, is a Reviewing Editor for eLife. Has received consultancy fees from Merck, University of Virginia Miller Center and Janssen, and has performed unpaid consultancy work for Janssen, Pfizer and Astra Zeneca. Has also received payments or honoraria from Sanofi Pasteur and Bristol Myers Squibb. ML has no other competing interests to declare..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1504-9213

Funding

Fogarty International Center (D43 TW009610)

  • Lerato E Magosi

Centers for Disease Control and Prevention (U01 GH000447 and U2G GH001911)

  • Lerato E Magosi
  • Janet Moore
  • Pam Bachanas
  • Refeletswe Lebelonyane
  • Molly Pretorius Holme
  • Shahin Lockman
  • Myron (Max) Essex

National Institutes of Health

  • Christophe Fraser
  • Marc Lipsitch

Bill and Melinda Gates Foundation

  • Christophe Fraser

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The BCPP study was approved by the Botswana Health Research and Development Committee and the institutional review board of the Centers for Disease Control and Prevention; and was monitored by a data and safety monitoring board and Westat. Written informed consent for enrollment in the study and viral HIV genotyping was obtained from all participants.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 1,053
    views
  • 170
    downloads
  • 15
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Lerato E Magosi
  2. Yinfeng Zhang
  3. Tanya Golubchik
  4. Victor DeGruttola
  5. Eric Tchetgen Tchetgen
  6. Vladimir Novitsky
  7. Janet Moore
  8. Pam Bachanas
  9. Tebogo Segolodi
  10. Refeletswe Lebelonyane
  11. Molly Pretorius Holme
  12. Sikhulile Moyo
  13. Joseph Makhema
  14. Shahin Lockman
  15. Christophe Fraser
  16. Myron (Max) Essex
  17. Marc Lipsitch
  18. on behalf of the Botswana Combination Prevention Project and the PANGEA consortium
(2022)
Deep-sequence phylogenetics to quantify patterns of HIV transmission in the context of a universal testing and treatment trial - BCPP/ Ya Tsie trial
eLife 11:e72657.
https://doi.org/10.7554/eLife.72657

Share this article

https://doi.org/10.7554/eLife.72657

Further reading

    1. Genetics and Genomics
    Jongkeun Park, WonJong Choi ... Dongwan Hong
    Research Article

    An unprecedented amount of SARS-CoV-2 data has been accumulated compared with previous infectious diseases, enabling insights into its evolutionary process and more thorough analyses. This study investigates SARS-CoV-2 features as it evolved to evaluate its infectivity. We examined viral sequences and identified the polarity of amino acids in the receptor binding motif (RBM) region. We detected an increased frequency of amino acid substitutions to lysine (K) and arginine (R) in variants of concern (VOCs). As the virus evolved to Omicron, commonly occurring mutations became fixed components of the new viral sequence. Furthermore, at specific positions of VOCs, only one type of amino acid substitution and a notable absence of mutations at D467 were detected. We found that the binding affinity of SARS-CoV-2 lineages to the ACE2 receptor was impacted by amino acid substitutions. Based on our discoveries, we developed APESS, an evaluation model evaluating infectivity from biochemical and mutational properties. In silico evaluation using real-world sequences and in vitro viral entry assays validated the accuracy of APESS and our discoveries. Using Machine Learning, we predicted mutations that had the potential to become more prominent. We created AIVE, a web-based system, accessible at https://ai-ve.org to provide infectivity measurements of mutations entered by users. Ultimately, we established a clear link between specific viral properties and increased infectivity, enhancing our understanding of SARS-CoV-2 and enabling more accurate predictions of the virus.

    1. Cell Biology
    2. Genetics and Genomics
    Showkat Ahmad Dar, Sulochan Malla ... Manolis Maragkakis
    Research Article

    Cells react to stress by triggering response pathways, leading to extensive alterations in the transcriptome to restore cellular homeostasis. The role of RNA metabolism in shaping the cellular response to stress is vital, yet the global changes in RNA stability under these conditions remain unclear. In this work, we employ direct RNA sequencing with nanopores, enhanced by 5ʹ end adapter ligation, to comprehensively interrogate the human transcriptome at single-molecule and -nucleotide resolution. By developing a statistical framework to identify robust RNA length variations in nanopore data, we find that cellular stress induces prevalent 5ʹ end RNA decay that is coupled to translation and ribosome occupancy. Unlike typical RNA decay models in normal conditions, we show that stress-induced RNA decay is dependent on XRN1 but does not depend on deadenylation or decapping. We observed that RNAs undergoing decay are predominantly enriched in the stress granule transcriptome while inhibition of stress granule formation via genetic ablation of G3BP1 and G3BP2 rescues RNA length. Our findings reveal RNA decay as a key component of RNA metabolism upon cellular stress that is dependent on stress granule formation.